Thalidomide
Light Chain Deposition Disease
Margarida Magalhaes-SilvermanSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Light Chain Deposition Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Brigham and Women's Hospital | Phase 3 | BB |
cc-5013 National Cancer Institute (NCI) | Phase 3 | B |
Inno-206 Margarida Magalhaes-Silverman | Phase 2 | B |
ETOPOSIDE Margarida Magalhaes-Silverman | Phase 2 | B |
Cyclophosphamide Margarida Magalhaes-Silverman | Phase 2 | B |
View all 10 →
Same molecule, other indications
Thalidomide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →